Patents by Inventor Xavier Collet

Xavier Collet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF
    Publication number: 20220218768
    Abstract: The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.
    Type: Application
    Filed: February 16, 2022
    Publication date: July 14, 2022
    Inventors: Remy BURCELIN, Francois TERCE, Estelle GRASSET, Jeffrey CHRISTENSEN, Xavier COLLET
  • Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
    Patent number: 11285180
    Abstract: The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: March 29, 2022
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Université Paul Sabatier Toulouse III
    Inventors: Remy Burcelin, Francois Terce, Estelle Grasset, Jeffrey Christensen, Xavier Collet
  • METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF
    Publication number: 20190388486
    Abstract: The present invention relates to methods of enhancing the potency of incretin-based drugs in subjects in need thereof. Through different animal models, the inventors identified that a specific gut microbiota signature impairs GLP-1-activated gut-brain axis which could be transferred to germ free mice. The dysbiotic gut microbiota induces enteric neuropathy, reduces GLP-1 receptor and nNOS mRNA concentration, GLP-1-induced nitric oxide production for the control of insulin secretion and gastric emptying. The frequency of Lactobacilli in the ileum microbiota was tightly correlated with nMOS mRNA concentration, which is a mode of action of GLP-1, of the enteric nervous system opening a novel route for the improvement of GLP-1 based therapies in type 2 diabetic patients. In particular, the present invention relates to a method of enhancing the potency of an incretin-based drug administered to a diabetic subject as part of a treatment regimen.
    Type: Application
    Filed: December 5, 2017
    Publication date: December 26, 2019
    Inventors: Remy BURCELIN, Francois TERCE, Estelle GRASSET, Jeffrey CHRISTENSEN, Xavier COLLET
  • Use of Atp Analogues for Treatment of Cardiovascular Diseases
    Publication number: 20070249555
    Abstract: Use of N-alkyl-2-substituted ATP analogues, pharmaceutically acceptable salts, metabolites or prodrugs thereof, for the preparation of a medicament intended to be used in the prevention and/or the treatment of cardiovascular diseases, pharmaceutical compositions comprising such compounds and a method for screening such compounds.
    Type: Application
    Filed: June 7, 2005
    Publication date: October 25, 2007
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Ronald Barbaras, Bertrand Perret, Corrine Rolland, Francois Terce, Jean-Marie Boeynaems, Xavier Collet, Sebastien Jacquet, Laurent Martinez
  • Lipoprotein receptor
    Publication number: 20040072368
    Abstract: This invention relates to the use of at least one domain of ATP synthase as a lipoprotein receptor.
    Type: Application
    Filed: September 12, 2002
    Publication date: April 15, 2004
    Inventors: Laurent Martinez, Sebastien Jacquet, Corinne Rolland, Francois Terce, Xavier Collet, Bertrand Perret, Ronald Barbaras, Eric Champagne, Jean-Pierre Esteve, John Walker, Michael Runswick